Eikon Therapeutics (EIKN) vs Lexeo Therapeutics (LXEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Eikon Therapeutics is the larger company by market cap ($256.8 million vs $245.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EIKN | LXEO |
|---|---|---|
| Share price | $4.74 | $2.96 |
| Market cap | $256.84M | $245.05M |
| 1-day change | -0.42% | +0.34% |
| YTD return | — | -70.19% |
| 1-year return | — | -67.33% |
| EPS (TTM) | $-7.86 | $-1.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-100.00M |
| 52-week high | $17.40 | $10.99 |
| 52-week low | $4.72 | $2.55 |
| Distance from 52-week high | -72.76% | -73.07% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +406.33% | +748.31% |
| Average volume | 560.40K | 1.98M |
| Shares outstanding | 54.19M | 82.79M |
| Employees | 384 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eikon Therapeutics
EIKN stock →Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees
EIKN vs LXEO FAQ
Which is bigger, Eikon Therapeutics or Lexeo Therapeutics?
Eikon Therapeutics (EIKN) is larger, with a market capitalization of $256.84M compared with $245.05M for Lexeo Therapeutics (LXEO).
Are Eikon Therapeutics and Lexeo Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.